Arbutus Biopharma Corp (ABUS) Trading Down 2.9%
Shares of Arbutus Biopharma Corp (NASDAQ:ABUS) dropped 2.9% during mid-day trading on Friday . The stock traded as low as $4.08 and last traded at $4.09, with a volume of 58,453 shares traded. The stock had previously closed at $4.21.
ABUS has been the topic of several research reports. Zacks Investment Research raised shares of Arbutus Biopharma Corp from a “hold” rating to a “buy” rating and set a $6.00 price target on the stock in a research report on Monday, April 25th. Leerink Swann reaffirmed a “buy” rating on shares of Arbutus Biopharma Corp in a report on Wednesday. Chardan Capital cut shares of Arbutus Biopharma Corp from a “neutral” rating to a “sell” rating and reduced their target price for the company from $3.25 to $2.75 in a report on Friday, July 8th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $20.00 target price on shares of Arbutus Biopharma Corp in a report on Wednesday, May 4th. One equities research analyst has rated the stock with a sell rating and five have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $10.96.
The stock’s market cap is $229.42 million. The firm’s 50 day moving average is $3.74 and its 200 day moving average is $3.92.
Arbutus Biopharma Corp (NASDAQ:ABUS) last announced its earnings results on Wednesday, May 4th. The biopharmaceutical company reported ($0.19) earnings per share for the quarter, beating the consensus estimate of ($0.39) by $0.20. Equities analysts forecast that Arbutus Biopharma Corp will post ($1.35) EPS for the current year.
Arbutus Biopharma Corporation, formerly Tekmira Pharmaceuticals Corporation, is a therapeutic solutions company. The Company is engaged in discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection (HBV), a disease of the liver caused by the hepatitis B virus (HBV).
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.